30-50 % was my talk about sp appreciation, which i still think is real. 70% is the US impression of the drugs chances. As you can see there is quite a mismatch in all these numbers
There are many similar companies in the uS with a few drugs in development and quite a lot of cash. I think this is the 1 year outlook for PYC. 1-2B US mcap, 3 drugs funded thru trials. Many permutations to get there, but US listing is the real key.
Is this the week?, page-74
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
14.0¢ |
Change
0.010(7.69%) |
Mkt cap ! $653.2M | |||
| Open | High | Low | Value | Volume |
| 14.0¢ | 14.5¢ | 13.0¢ | $1.446M | 10.38M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 252759 | 13.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.0¢ | 113762 | 2 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| PYC (ASX) Chart |